

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER POR PATENTS PO Box (430) Alexandria, Virginia 22313-1450 www.orupo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/656,192	09/08/2003	Mark J. Cooper	003659.00029	8424	
22907 BANNER & V	7590 03/09/2009 WITCOFF, LTD.	EXAM	EXAMINER		
1100 13th STREET, N.W.			LONG, SCOTT		
SUITE 1200 WASHINGTO	ON, DC 20005-4051	ART UNIT	PAPER NUMBER		
(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)			1633		
			MAIL DATE	DELIVERY MODE	
			03/09/2009	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

	Application No.	Applicant(s)		
10/656,192		COOPER ET AL.		
	Examiner	Art Unit		
	SCOTT LONG	1633		
	SCOTT LONG	1000		

5	SCOTT LONG	1633	
The MAILING DATE of this communication appear	rs on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED 27 January 2009 FAILS TO PLACE THIS AP	PLICATION IN CONDITION FOR	R ALLOWANCE.	
 \(\times \) The reply was filed after a final rejection, but prior to or on the application, applicant must timely file one of the following reapplication in condition for allowance; (2) a Notice of Appea for Continued Examination (RCE) in compliance with 37 CF periods: \(\times \) The period for reply expires 3 months from the mailing date of 	ne same day as filing a Notice of A plies: (1) an amendment, affidavit I (with appeal fee) in compliance of R 1.114. The reply must be filed of the final rejection.	Appeal. To avoid abar , or other evidence, w with 37 CFR 41.31; or within one of the follow	hich places the (3) a Request ving time
b) The period for reply expires on: (1) the mailing date of this Adv no event, however, will the statutory period for reply expire late Examiner Note: If box 1 is checked, check either box (a) or (b)	er than SIX MONTHS from the mailing	date of the final rejection	n.
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on			
have been filed is the date for purposes of determining the period of exter under 37 CFR 1.17(a) is calculated from: (1) the explaint of add of the set forth in (b) above, if checked. Any reply received by the Office later th may reduce any earned patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	nsion and the corresponding amount of ortened statutory period for reply origin	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as
The Notice of Appeal was filed on A brief in complie filing the Notice of Appeal (37 CFR 41.37(a)), or any extens Notice of Appeal has been filed, any reply must be filed with	ion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
AMENDMENTS			
 The proposed amendment(s) filed after a final rejection, but They raise new issues that would require further cons They raise the issue of new matter (see NOTE below) 	ideration and/or search (see NOT		cause
 (c) They are not deemed to place the application in bette appeal; and/or 	r form for appeal by materially red	lucing or simplifying th	ne issues for
(d) ☐ They present additional claims without canceling a co NOTE: (See 37 CFR 1.116 and 41.33(a)).	rresponding number of finally reje	cted claims.	
4. The amendments are not in compliance with 37 CFR 1.121		mpliant Amendment (f	PTOL-324).
 Applicant's reply has overcome the following rejection(s): Newly proposed or amended claim(s) would be allow non-allowable claim(s). 		imely filed amendmer	t canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is provid The status of the claim(s) is or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) withdrawn from consideration:		be entered and an ex	planation of
AFFIDAVIT OR OTHER EVIDENCE			
The affidavit or other evidence filed after a final action, but the because applicant failed to provide a showing of good and swas not earlier presented. See 37 CFR 1.116(e).			
 The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to ove showing a good and sufficient reasons why it is necessary a 	ercome <u>all</u> rejections under appea and was not earlier presented. Se	l and/or appellant fails e 37 CFR 41.33(d)(1)	s to provide a
10. The affidavit or other evidence is entered. An explanation of REQUEST FOR RECONSIDERATION/OTHER	of the status of the claims after en	try is below or attache	ed.
11. The request for reconsideration has been considered but of See Continuation Sheet.	loes NOT place the application in	condition for allowan	ce because:
12. Note the attached Information <i>Disclosure Statement</i> (s). (P 13. Other:	TO/SB/08) Paper No(s)		
	/Janet L. Epps-Smith/ Primary Examiner, Art U	nit 1633	

Continuation of 11. does NOT place the application in condition for allowance because: The applicant has submitted additional arguments and a request for reconsideration. No claim amendments were submitted.

The applicant argues that the instant claims have 4 physical properties: (1) rod-shaped, (2) diameter of 10-20 nm, (3) condensed, and (4) single nucleic acid molecule.

Claim 1 is a product-by-process claim. The composition comprising said complexes are formed by mixing said nucleic acid molecule and polycation molecules...* Hanson makes DNA/polycation complexes by the same procedure described by incidal claim 1. This has been discussed numerous times during the course of prosecution. As previously discussed, this procedure results in complexes having a heterogeneous mixture of shapes. Both the art and the specification onfirm this. The applicant has chosen to amend their claims to focus on the structure of a single complex form, even though the applicant and specification acknowledge that there are actually many shapes present in the claimed composition. Since Hanson et al. (US-5844107) practices the process described in claim 1, therefore the product (i.e., rod-shaped, 10-20nm diameter, condensed, single nucleic acid molecule complexes) is inherently produced. The claimed composition is not limited to only rod-shaped condensed nucleic acid molecule process, relating the composition COMPRISES rod-shaped condensed complexes, meaning nod-shaped.

Because claim 1 is a product-by-process claim and Hanson et al. teaches this process, the examiner asserts that such a rod-shaped complex is formed. Clearly, the examiner and applicant disagree on Hanson's verification of such a rod-shaped form. If the applicant honestly feels Hanson does not anticipate or is not obvious over the the instant claims, the examiner suggests the applicant appeal to the BPAI. The examiner does not find the applicant's arguments persuasive.

Accordingly, the examiner hereby maintains the rejection of the pending claims for the reasons of record and the comments above.

/SDL/ Scott Long patent examiner, art unit 1633.